MYND Life Sciences Inc.

As of July 31, 2024, MYND Life Sciences Inc. has 47.82M shares outstanding.

These figures are as of July 31, 2024. The price-to-sales ratio is 1.86M, and the price-to-book ratio stands at -0.32.

These figures are as of July 31, 2024. The EV/Sales ratio of 4.91M reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. MYND Life Sciences Inc. trades at an EV/FCF ratio of 74.82, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of July 31, 2024, MYND Life Sciences Inc. maintains a current ratio of 0.09, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -50.09, indicating conservative leverage, while an interest coverage ratio of -5.38 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended July 31, 2024. Return on assets (ROA) is negative at -102.24, reflecting losses generated across the asset base. Return on capital employed (ROCE) is 0.76, useful for judging operating efficiency across full business cycles.

Over the twelve months ended July 31, 2024, MYND Life Sciences Inc. posted a gross margin of -24.00M, reflecting its pricing power and cost economics. The operating margin of -128.60M and net profit margin of -54.26M provide insight into operational efficiency.

These figures cover the twelve months ended July 31, 2024. Free cash flow yield is negative at -9.28: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

As of July 31, 2024, MYND Life Sciences Inc. has an Altman Z-Score of -36.35, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.